The Renaissance of Psychedelic Medicine
DOI:
https://doi.org/10.52076/eacad-v3i3.298Keywords:
Psilocybin; Psychedelic; Depression; Anxiety; Alternative medicine.Abstract
Introduction: Studies about alternative medicine have multiplied in several countries such as the United States, Norway and England in recent years. Among them, I highlight psychedelic medicine that through randomized clinical trials, has already shown that psilocybin - substance present in the Psilocybe cubensis mushroom, popularly known as "magic mushrooms" - was able to induce remission of depression and anxiety symptoms, in addition to other beneficial effects that culminated in an increase of the life quality with low rate of negative effects, demonstrating a great therapeutic potential in the management of mental disorders refractory to conventional treatments. Objective of the article: This article aims to promote the discussion about psychedelic medicine, analyzing the personal experience and the interest of the population about it, which unfortunately still lacks of national studies. Methodology: Consists of an observational study in which data were obtained through the application of an online questionnaire on the Google forms platform. 12 variables were analyzed and included epidemiological data, whether the individual had any psychedelic experiences and what were the observed effects and how relevant you consider the subject. Conclusion: The total sample was 203 participants, 74 of whom had already consumed psilocybin and the majority considered it a positive experience, as 89.2% (N=66) of them stated that they would use it again. The only factor that influenced the classification of the experience was having prior knowledge about researches in this area and most participants (67.5%) considered the topic as super relevant.
References
PEREIRA, A. A. et. al. (2018). Free e-book: Metodologia da pesquisa científica.Santa Maria/RS. Ed. UAB/NTE/UFSM. Disponível em: https://repositorio.ufsm.br/handle/1/15824.
A. HOFMANN. et al. (1959). Helvetica Chimica Acta: Troxler Psilocybin und Psilocin, zwei psychotrope Wirkstoffe aus mexikanischen Rauschpilzen. V. 42, I.5 P. 1557-1572. Disponível em: https://onlinelibrary.wiley.com/doi/10.1002/hlca.19590420518.
BRADLEY N. GAYNES. et. al. (2009). Psychiatric Services: What Did STAR*D Teach Us? Results From a Large-Scale, Practical, Clinical Trial for Patients With Depression. v. 60. n. 11. p.1439–1445. Disponível em: http://psychiatryonline.org/doi/abs/10.1176/ps.2009.60.11.1439.
CHARLES B. NEMEROFF. (2007). The Journal of clinical psychiatry: Prevalence and management of treatment-resistant depression. v. 68 n. 8. p. 17–25. Disponível em: https://www.psychiatrist.com/jcp/depression/prevalence-management-treatment-resistant-depression/.
DAVID NUTT. et. al. (2020). Cell: Psychedelic Psychiatry’s Brave New World. v. 181. n. 1. p. 24–28. Disponível em: https://linkinghub.elsevier.com/retrieve/pii/S0092867420302828.
DAVID NUTT. (2019). Dialogues in Clinical Neuroscience: Psychedelic drug - a new era in psychiatry? v. 21. n. 2. p. 139–147. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787540/.
DAVID NUTT. et. al. (2010). The Lancet: Drug harms in the UK: a multicriteria decision analysis. v. 376. n. 9752. p. 1558–1565. Disponível em: https://linkinghub.elsevier.com/retrieve/pii/S0140673610614626.
JAMES J. H. RUCKERT. et. al. (2018). Neuropharmacology: Psychiatry e amp the psychedelic drugs. Past, present & future. v. 142. p. 200–218. Disponível em: <https://linkinghub.elsevier.com/retrieve/pii/S002839081730638X.
ORGANIZAÇÃO MUNDIAL DA SAÚDE (OMS). (2021). Depression fact sheet. Disponível em: https://www.who.int/en/news-room/fact-sheets/detail/depression.
ORGANIZAÇÃO PAN-AMERICANA DA SAÚDE (OPAS). (2021). Depressão. Disponível em: https://www.paho.org/pt/topicos/depressao.
ROBIN L. CARHART-HARRIS. et. al. (2021). N Engl J Med: Trial of Psilocybin versus Escitalopram for Depression. 384:1402-1411. Disponível em: https://www.nejm.org/doi/full/10.1056/NEJMoa2032994.
ROBIN L. CARHART-HARRIS.. et al. (2018). Psychopharmacology: Psilocybin with psychological support for treatment- resistant depression: six-month follow-up.v. 235. n. 2. p. 399–408. Disponível em: https://link.springer.com/article/10.1007/s00213-017-4771-x
ROBIN L. CARHART-HARRIS. et al. (2016). The Lancet Psychiatry: Psilocybin with psychological support for treatment- resistant depression: an open-label feasibility study. v. 3. n. 7. p. 619–627. Disponível em: https://www.sciencedirect.com/science/article/pii/S2215036616300657.
ROBIN L. CARHART-HARRIS. et al. (2017). Scientific Reports: Psilocybin for treatment-resistant depression: fMRI- measured brain mechanisms. v. 7, n. 1, p. 13-87. Disponível em: http://www.nature.com/articles/s41598-017-13282-7.
ROLAND R. GRIFFITHS et. al. (2018). Journal of Psychopharmacology: Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors.
v. 32. n. 1. p. 49–69. Disponível em: http://journals.sagepub.com/doi/10.1177/0269881117731279.
ROLAND. R. GRIFFITHS. et. al. (2016). Journal of Psychopharmacology: Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double- blind trial. v.30. n.12. p.1181–1197.
Disponível em: https://journals.sagepub.com/doi/10.1177/0269881116675513.
ROLAND R. GRIFFITHS. et. al. (2008). Journal of Psychopharmacology: Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. v. 22. n. 6. p. 621–632. Disponível em: http://journals.sagepub.com/doi/10.1177/0269881108094300.
STEPHEN ROSS et. al. (2016). Journal of Psychopharmacology: Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. v. 30. n. 12. p. 1165–1180. Disponível em: http://journals.sagepub.com/doi/10.1177/0269881116675512.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Roberto Carlos Moreira Kuligowski; Eduarda Maria Schroeder ; João Vitor Pelizzari ; Matheus Fortunato; Rafael Osorio Cavalli
This work is licensed under a Creative Commons Attribution 4.0 International License.
Autores que publicam nesta revista concordam com os seguintes termos:
1) Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista.
2) Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
3) Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado.